MARKET

TPST

TPST

Tempest Therapeutics Inc
NASDAQ
2.320
-0.100
-4.13%
Opening 12:49 02/11 EST
OPEN
2.340
PREV CLOSE
2.420
HIGH
2.405
LOW
2.160
VOLUME
85.39K
TURNOVER
--
52 WEEK HIGH
12.48
52 WEEK LOW
2.160
MARKET CAP
11.43M
P/E (TTM)
-0.2231
1D
5D
1M
3M
1Y
5Y
1D
BUZZ-U.S. STOCKS ON THE MOVE-Klaviyo, Frontier Group, Wabtec
Reuters · 5h ago
BUZZ-U.S. STOCKS ON THE MOVE-Shopify, GlobalFoundries, Constellation Energy
Reuters · 7h ago
BUZZ-Tempest Therapeutics rises on partner‑funded plan for new cancer drugs
Reuters · 8h ago
BRIEF-Tempest Lays Out Strategic Plan To Advance Recently Acquired Dual-Targeting Car-T Assets
Reuters · 9h ago
Tempest Therapeutics Outlines Future Plans to Advance Dual-Targeting CAR-T Programs, Expand In Vivo Pipeline, and Pursue Partner-Funded Development Strategies
Reuters · 9h ago
TEMPEST THERAPEUTICS INC - TO INITIATE PHASE 2 STUDY OF TPST-1495 IN Q1 2026
Reuters · 9h ago
Weekly Report: what happened at TPST last week (0202-0206)?
Weekly Report · 2d ago
Tempest Therapeutics Overhauls Leadership and Acquires New Assets
TipRanks · 4d ago
More
About TPST
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are Amezalpat and TPST-1495. Amezalpat is an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha. The ongoing global randomized Phase Ib/II trial of Amezalpat combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, a pathway implicated in multiple cancers.

Webull offers Tempest Therapeutics Inc stock information, including NASDAQ: TPST real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TPST stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TPST stock methods without spending real money on the virtual paper trading platform.